BCL2 and Sepsis: This finding challenges the limitations of traditional immunosuppressive theories of sepsis and provides an innovative theoretical foundation for targeting CD4+ T cells or the Bcl-2 pathway in the treatment of sepsis (Stromberg et al., 2009).